Literature DB >> 12069532

Mechanisms of protection induced by attenuated simian immunodeficiency virus.

Richard J Stebbings1, Neil M Almond, E Jim Stott, Neil Berry, Alison M Wade-Evans, Robin Hull, Jenny Lines, Peter Silvera, Rebecca Sangster, Terry Corcoran, Jane Rose, K Barry Walker.   

Abstract

To determine whether attenuated simian immunodeficiency virus (SIV) vaccines confer protection against superinfection via secondary cellular immune responses, we searched for markers of immune activation following rechallenge. Productive infection with either attenuated SIVmacC8 or wild-type SIVmacJ5 resulted in a transient increase in T-lymphocyte CD25 and Mafa-DR expression. A pronounced increase in the frequency of FAS+ CD8+ lymphocytes was observed following SIVmacJ5 infection only. A transient increase in lymphocytes positive for intracellular IFN-gamma and IL-4 was observed following primary infection with either virus. In contrast, lymphocytes positive for intracellular IL-2 were reduced. Following SIVmacJ5 challenge of SIVmacC8-infected vaccinees, no evidence of detectable superinfection was obtained. Rechallenge of vaccinees did not alter the frequency of activated peripheral T-lymphocytes, perturb cytokine profiles, or generate an anamnestic antibody response. These data do not support the hypothesis that protection conferred by live attenuated SIV is mediated by the induction of vigorous T-cell responses upon rechallenge.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069532     DOI: 10.1006/viro.2002.1379

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques.

Authors:  Edward T Mee; Neil Berry; Claire Ham; Ulrike Sauermann; Maria T Maggiorella; Frédéric Martinon; Ernst J Verschoor; Jonathan L Heeney; Roger Le Grand; Fausto Titti; Neil Almond; Nicola J Rose
Journal:  Immunogenetics       Date:  2009-04-01       Impact factor: 2.846

2.  Prevention of immunodeficiency virus induced CD4+ T-cell depletion by prior infection with a non-pathogenic virus.

Authors:  Julie A Terwee; Jennifer K Carlson; Wendy S Sprague; Kerry S Sondgeroth; Sarah B Shropshire; Jennifer L Troyer; Sue VandeWoude
Journal:  Virology       Date:  2008-05-22       Impact factor: 3.616

3.  A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease.

Authors:  Rama Rao Amara; Kalpana Patel; Genevieve Niedziela; Pragati Nigam; Sunita Sharma; Silvija I Staprans; David C Montefiori; Lakshmi Chenareddi; James G Herndon; Harriet L Robinson; Harold M McClure; Francis J Novembre
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus.

Authors:  Richard Stebbings; Neil Berry; Herman Waldmann; Pru Bird; Geoff Hale; Jim Stott; David North; Robin Hull; Joanna Hall; Jenny Lines; Stuart Brown; Nikki D'Arcy; Leanne Davis; William Elsley; Cherry Edwards; Deborah Ferguson; Jane Allen; Neil Almond
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 5.  Non-human primate models for AIDS vaccine research.

Authors:  Shiu-Lok Hu
Journal:  Curr Drug Targets Infect Disord       Date:  2005-06

6.  Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses.

Authors:  Kristina Abel; Lara Compton; Tracy Rourke; David Montefiori; Ding Lu; Kristina Rothaeusler; Linda Fritts; Kristen Bost; Christopher J Miller
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo.

Authors:  Justin M Greene; Jennifer J Lhost; Benjamin J Burwitz; Melisa L Budde; Caitlin E Macnair; Madelyn K Weiker; Emma Gostick; Thomas C Friedrich; Karl W Broman; David A Price; Shelby L O'Connor; David H O'Connor
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus.

Authors:  Klara Tenner-Racz; Christiane Stahl Hennig; Klaus Uberla; Heribert Stoiber; Ralf Ignatius; Jonathan Heeney; Ralph M Steinman; Paul Racz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

10.  Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate.

Authors:  Wendy W Yeh; Pimkwan Jaru-Ampornpan; Daiva Nevidomskyte; Mohammed Asmal; Srinivas S Rao; Adam P Buzby; David C Montefiori; Bette T Korber; Norman L Letvin
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.